Melanoma-associated antigen 1-specific T cell receptor (MAGE-A1 TCR)

Melanoma-associated antigen 1 (MAGE-A1) is a member of the cancer-testis antigen (CTA) family, characterized by its expression in various malignant tumors while remaining silent in normal adult tissues, except for immune-privileged germ cells in the testis (UniProt P43355; Science, 1991). T cell receptors (TCRs) specific for MAGE-A1 are engineered into adaptive immune cells, such as T cells, to create TCR-T cell therapies that target and eliminate MAGE-A1-expressing cancer cells (ClinicalTrials.gov NCT05419050; Frontiers in Oncology, 2021). These TCRs are designed to recognize specific MAGE-A1 peptide fragments, such as EADPTGHSY, presented by human leukocyte antigen (HLA) molecules, most commonly HLA-A*01:01 (Science, 1991). Upon binding to the peptide-MHC complex, the TCR-T cells undergo activation, proliferate, and release cytotoxic granules and pro-inflammatory cytokines to induce tumor cell death (Frontiers in Oncology, 2021). This therapeutic approach is currently being evaluated in clinical trials for patients with advanced solid tumors, including melanoma and non-small cell lung cancer, where MAGE-A1 serves as a highly specific tumor target (NCT05419050). However, a critical challenge in developing these TCRs is ensuring high specificity to avoid cross-reactivity with other MAGE family members or unrelated proteins in healthy tissues, which could lead to severe off-target toxicities (Blood, 2013).

Other names

MAGE-A1-specific TCRMAGE-A1-targeted T-cell receptorAnti-MAGE-A1 TCRMAGE-A1-specific T-cell receptorMAGE-A1 TCR-T

Engineered T cells expressing the MAGE-A1-specific TCR recognize the MAGE-A1 peptide-HLA complex (typically HLA-A*01:01) on the surface of tumor cells, triggering T cell activation, expansion, and the release of cytotoxic molecules like granzymes and perforin to induce apoptosis in the target cell (Science, 1991; Frontiers in Oncology, 2021).